Hospital
Adena Health System
Adena Health System was paid $98.12M by Medicaid between Jan 2018 and Dec 2024, across 694 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 15% of everything it billed.
33Billing provider infoADENA HEALTH SYSTEM
CHILLICOTHE, OH 45601
CHILLICOTHE, OH 45601
33aNPI1902839673assigned 07/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$98.12M
24GClaims2,548,012
24DCodes billed694
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#10 of 101
Median peer was paid$22.32M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 228,670 | $7.82M | |
| 2019 | 220,396 | $7.67M | |
| 2020 | 204,278 | $9.78M | |
| 2021 | 214,137 | $10.57M | |
| 2022 | 242,646 | $10.19M | |
| 2023 | 855,438 | $28.82M | |
| 2024incomplete | 582,447 | $23.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 15% | 215,041 | 164,768 | $14.44M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 13% | 140,877 | 129,688 | $12.95M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.3% | 85,986 | 78,637 | $9.10M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.9% | 55,090 | 48,974 | $5.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.8% | 43,650 | 40,645 | $4.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.8% | 31,634 | 28,089 | $3.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 20,405 | 14,190 | $2.13M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 32,341 | 8,545 | $2.08M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.7% | 17,137 | 15,648 | $1.66M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.4% | 12,907 | 11,978 | $1.36M |
| G0378 | Hospital observation service, per hour | 1.3% | 23,456 | 8,119 | $1.31M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 5,236 | 3,790 | $1.19M |
682 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 5,532 | $1.17M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,956 | $976K |
| 20610 | <1% | 7,187 | $899K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,330 | $845K |
| 95886 | <1% | 4,681 | $809K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,483 | $809K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,762 | $790K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 11,288 | $783K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,785 | $765K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,299 | $707K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,867 | $689K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 10,316 | $683K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,124 | $678K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,049 | $616K |
| 80053 | Comprehensive metabolic panel | <1% | 58,965 | $555K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 4,478 | $504K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 5,232 | $484K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,077 | $478K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 55,751 | $453K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,194 | $451K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 120 | $446K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,158 | $434K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,690 | $382K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,064 | $379K |
| 59025 | Fetal non-stress test | <1% | 2,254 | $374K |
| 87081 | <1% | 18,387 | $365K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 124,627 | $360K |
| 29848 | <1% | 324 | $344K | |
| J3490 | Unclassified drugs | <1% | 30,734 | $319K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,240 | $312K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 224 | $307K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,765 | $305K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,795 | $296K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,369 | $290K |
| 90837 | Psychotherapy session, about an hour | <1% | 2,149 | $287K |
| 20611 | <1% | 1,404 | $285K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,468 | $285K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,814 | $280K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 3,093 | $279K |
| 95180 | <1% | 537 | $259K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,228 | $253K |
| 64493 | <1% | 503 | $250K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 632 | $240K |
| 96127 | <1% | 2,537 | $239K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 4,306 | $238K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,713 | $232K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,166 | $221K |
| 36415 | Collection of venous blood by venipuncture | <1% | 165,634 | $220K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 471 | $218K |
| 95117 | <1% | 7,020 | $214K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,387 | $212K |
| 93458 | <1% | 274 | $207K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,188 | $198K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 414 | $197K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,755 | $191K |
| 11102 | <1% | 687 | $191K | |
| 70496 | <1% | 831 | $189K | |
| 80061 | Lipid panel | <1% | 20,949 | $186K |
| 96415 | <1% | 836 | $184K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,810 | $179K |
| 47562 | <1% | 88 | $178K | |
| 17311 | <1% | 471 | $176K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,188 | $176K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,865 | $170K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25,315 | $166K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,665 | $161K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 10,401 | $154K |
| 17110 | <1% | 1,366 | $153K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,215 | $151K |
| 87088 | <1% | 14,927 | $148K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 601 | $144K |
| 76830 | Ultrasound, transvaginal | <1% | 1,850 | $141K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,920 | $140K |
| 73630 | <1% | 4,789 | $138K | |
| 64483 | <1% | 342 | $137K | |
| 82607 | <1% | 9,831 | $123K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 599 | $122K |
| 64635 | <1% | 329 | $121K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 709 | $120K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,370 | $119K |
| 97161 | <1% | 2,166 | $119K | |
| 95811 | <1% | 201 | $117K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,831 | $115K |
| 92557 | <1% | 1,831 | $114K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 528 | $114K |
| 76642 | <1% | 947 | $111K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 752 | $111K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,091 | $108K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,308 | $106K |
| 11721 | <1% | 4,703 | $102K | |
| 72141 | <1% | 674 | $101K | |
| 93017 | <1% | 1,440 | $101K | |
| 86850 | <1% | 5,450 | $100K | |
| 73221 | <1% | 540 | $100K | |
| 90686 | <1% | 9,782 | $100K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 37,560 | $98K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 6,378 | $98K |
| 73610 | <1% | 3,083 | $97K | |
| 97162 | <1% | 1,968 | $95K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,415 | $94K |
| 72100 | <1% | 4,363 | $91K | |
| 71250 | <1% | 1,200 | $91K | |
| 94060 | <1% | 820 | $90K | |
| 90648 | <1% | 11,134 | $88K | |
| 95806 | <1% | 304 | $87K | |
| 73130 | <1% | 2,691 | $86K | |
| 75574 | <1% | 266 | $83K | |
| 93975 | <1% | 980 | $83K | |
| 84484 | <1% | 25,847 | $82K | |
| 17000 | <1% | 970 | $81K | |
| 96367 | <1% | 1,549 | $81K | |
| 73562 | <1% | 2,511 | $78K | |
| Q3014 | Telehealth originating site facility fee | <1% | 7,059 | $77K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 124 | $77K |
| 73110 | <1% | 2,716 | $76K | |
| 62323 | <1% | 236 | $76K | |
| 0352U | <1% | 4,122 | $74K | |
| 86780 | <1% | 4,750 | $73K | |
| 90677 | <1% | 2,872 | $71K | |
| 74174 | <1% | 1,111 | $70K | |
| 86900 | <1% | 5,544 | $70K | |
| 31575 | <1% | 517 | $70K | |
| 90670 | <1% | 9,549 | $69K | |
| 95909 | <1% | 867 | $67K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,438 | $66K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,589 | $66K |
| 76770 | <1% | 489 | $66K | |
| 70491 | <1% | 296 | $65K | |
| 73030 | <1% | 2,812 | $64K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,759 | $64K |
| 93971 | <1% | 998 | $57K | |
| 52000 | <1% | 141 | $57K | |
| 97165 | <1% | 955 | $56K | |
| 80069 | <1% | 3,408 | $56K | |
| 96161 | <1% | 489 | $55K | |
| 76536 | <1% | 555 | $55K | |
| 82728 | <1% | 6,825 | $54K | |
| 58661 | <1% | 32 | $54K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,445 | $54K |
| 77336 | <1% | 563 | $53K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 342 | $53K |
| 80076 | <1% | 9,282 | $52K | |
| 74018 | <1% | 2,130 | $52K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 901 | $50K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 26,223 | $50K |
| 84439 | <1% | 4,882 | $49K | |
| 95911 | <1% | 277 | $49K | |
| 99385 | <1% | 764 | $49K | |
| 71271 | <1% | 254 | $49K | |
| 93225 | <1% | 531 | $48K | |
| 83970 | <1% | 2,221 | $47K | |
| 93970 | <1% | 407 | $47K | |
| 95816 | <1% | 322 | $46K | |
| 84466 | <1% | 7,402 | $46K | |
| 85027 | <1% | 9,212 | $45K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,278 | $44K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 1,215 | $44K |
| 93922 | <1% | 626 | $43K | |
| 92567 | <1% | 3,148 | $43K | |
| 72040 | <1% | 1,604 | $43K | |
| 73564 | <1% | 1,930 | $43K | |
| 94726 | <1% | 699 | $43K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 11,241 | $42K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 36 | $42K |
| 86803 | <1% | 2,899 | $41K | |
| 82565 | <1% | 9,662 | $40K | |
| 82570 | <1% | 6,584 | $40K | |
| 83540 | <1% | 7,778 | $40K | |
| 90633 | <1% | 4,958 | $40K | |
| 77334 | <1% | 137 | $39K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 197 | $38K |
| 90715 | <1% | 2,786 | $38K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,917 | $37K |
| 43235 | <1% | 119 | $37K | |
| 20550 | <1% | 224 | $37K | |
| 93454 | <1% | 46 | $37K | |
| 87147 | <1% | 3,663 | $36K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,931 | $34K |
| 86140 | <1% | 5,326 | $34K | |
| 87902 | <1% | 263 | $33K | |
| 90651 | <1% | 1,664 | $33K | |
| 77386 | <1% | 82 | $32K | |
| 94729 | <1% | 638 | $32K | |
| 76000 | <1% | 416 | $32K | |
| 83735 | <1% | 14,569 | $31K | |
| 93880 | <1% | 449 | $30K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,673 | $30K |
| 81001 | <1% | 27,741 | $30K | |
| 84702 | <1% | 3,071 | $29K | |
| 87340 | <1% | 2,548 | $27K | |
| 73140 | <1% | 1,058 | $27K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 140 | $27K |
| 64494 | <1% | 461 | $27K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 276 | $27K |
| 73080 | <1% | 989 | $27K | |
| 86762 | <1% | 1,577 | $27K | |
| 36430 | <1% | 312 | $27K | |
| 97012 | <1% | 836 | $27K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 853 | $27K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,114 | $26K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,803 | $26K |
| 29581 | <1% | 315 | $26K | |
| 88307 | <1% | 511 | $26K | |
| 73502 | <1% | 1,456 | $26K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 42 | $25K |
| 72131 | <1% | 821 | $25K | |
| 85610 | <1% | 20,547 | $25K | |
| 97166 | <1% | 582 | $24K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 849 | $24K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,489 | $24K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 359 | $24K |
| 87186 | <1% | 4,661 | $24K | |
| 88341 | <1% | 463 | $23K | |
| 82248 | <1% | 15,775 | $23K | |
| 82043 | <1% | 4,925 | $23K | |
| 90723 | <1% | 4,242 | $23K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 692 | $23K |
| 73701 | <1% | 93 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 693 | $23K |
| 11100 | <1% | 145 | $23K | |
| 86901 | <1% | 5,546 | $22K | |
| 20552 | <1% | 213 | $21K | |
| 77066 | Tomosynthesis, mammo | <1% | 594 | $20K |
| 70498 | <1% | 881 | $20K | |
| 77300 | <1% | 64 | $20K | |
| 12001 | <1% | 114 | $20K | |
| 90680 | <1% | 3,566 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,254 | $20K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 176 | $20K |
| 94618 | <1% | 427 | $20K | |
| 77080 | <1% | 311 | $19K | |
| 99205 | Prolong outpt/office vis | <1% | 309 | $19K |
| 86038 | <1% | 1,262 | $19K | |
| 71101 | <1% | 516 | $19K | |
| 83655 | <1% | 2,235 | $19K | |
| 99381 | <1% | 278 | $18K | |
| 87481 | <1% | 1,060 | $18K | |
| 82947 | <1% | 9,741 | $18K | |
| 82746 | <1% | 2,258 | $18K | |
| 97116 | <1% | 1,084 | $18K | |
| 29075 | <1% | 157 | $17K | |
| 90716 | <1% | 1,723 | $17K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,578 | $17K |
| 31231 | <1% | 78 | $17K | |
| 84403 | <1% | 1,345 | $17K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 725 | $17K |
| 74019 | <1% | 495 | $16K | |
| 84460 | <1% | 3,389 | $16K | |
| 11104 | <1% | 48 | $16K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,627 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,269 | $16K |
| 64636 | <1% | 319 | $16K | |
| 99384 | <1% | 253 | $16K | |
| 90707 | <1% | 3,466 | $16K | |
| 87070 | <1% | 1,898 | $15K | |
| 73222 | <1% | 50 | $15K | |
| 99386 | <1% | 289 | $15K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 468 | $15K |
| 11056 | <1% | 126 | $15K | |
| 86480 | <1% | 618 | $15K | |
| 97016 | <1% | 566 | $15K | |
| 73590 | <1% | 798 | $15K | |
| 84153 | <1% | 1,605 | $15K | |
| 70486 | <1% | 487 | $14K | |
| 82948 | <1% | 9,020 | $14K | |
| 80074 | <1% | 1,583 | $14K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 974 | $14K |
| 73090 | <1% | 568 | $14K | |
| 83525 | <1% | 909 | $14K | |
| 72072 | <1% | 508 | $14K | |
| 87507 | <1% | 232 | $14K | |
| 94660 | <1% | 169 | $14K | |
| 87510 | <1% | 746 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,624 | $13K |
| 84703 | <1% | 8,170 | $13K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,534 | $13K |
| 83690 | <1% | 15,258 | $13K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 166 | $12K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 230 | $12K |
| 91322 | <1% | 340 | $12K | |
| 74183 | <1% | 40 | $12K | |
| 97802 | <1% | 131 | $12K | |
| 84156 | <1% | 2,792 | $11K | |
| 72128 | <1% | 549 | $11K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 41 | $11K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 947 | $11K |
| 97803 | <1% | 134 | $11K | |
| 87480 | <1% | 746 | $11K | |
| 90734 | <1% | 1,640 | $11K | |
| 90696 | <1% | 1,313 | $11K | |
| 76801 | <1% | 1,177 | $11K | |
| 84450 | <1% | 2,262 | $11K | |
| 86787 | <1% | 1,367 | $11K | |
| 83880 | <1% | 5,184 | $10K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 962 | $10K |
| 73522 | <1% | 592 | $10K | |
| 86376 | <1% | 954 | $10K | |
| 81003 | <1% | 16,041 | $10K | |
| 96376 | <1% | 4,050 | $10K | |
| 93226 | <1% | 170 | $10K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,014 | $10K |
| 96368 | <1% | 709 | $10K | |
| 99407 | <1% | 307 | $10K | |
| 83001 | <1% | 861 | $10K | |
| 85652 | <1% | 4,235 | $10K | |
| 73560 | <1% | 377 | $10K | |
| 99152 | <1% | 1,422 | $9K | |
| 82077 | <1% | 4,265 | $9K | |
| 99406 | <1% | 578 | $9K | |
| 90620 | <1% | 658 | $9K | |
| 93296 | <1% | 669 | $9K | |
| 85730 | <1% | 7,634 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 19,533 | $9K |
| 92523 | <1% | 109 | $9K | |
| 84146 | <1% | 735 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,296 | $9K |
| 80197 | <1% | 436 | $9K | |
| 72070 | <1% | 447 | $9K | |
| 82670 | <1% | 599 | $9K | |
| 87205 | <1% | 1,900 | $8K | |
| 82533 | <1% | 1,150 | $8K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 459 | $8K |
| 11719 | <1% | 362 | $8K | |
| 72114 | <1% | 537 | $8K | |
| 81025 | <1% | 8,448 | $8K | |
| 95861 | <1% | 25 | $8K | |
| 84402 | <1% | 580 | $8K | |
| 87660 | <1% | 753 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 515 | $8K |
| 86431 | <1% | 978 | $8K | |
| 82247 | <1% | 817 | $8K | |
| 83605 | <1% | 6,852 | $7K | |
| 77290 | <1% | 18 | $7K | |
| 11730 | <1% | 56 | $7K | |
| 82105 | <1% | 1,050 | $7K | |
| 36410 | <1% | 516 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,954 | $7K |
| 11750 | <1% | 20 | $7K | |
| 86706 | <1% | 525 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 229 | $7K |
| 64615 | <1% | 38 | $7K | |
| 00840 | <1% | 606 | $7K | |
| 99383 | <1% | 98 | $7K | |
| 82950 | <1% | 1,037 | $7K | |
| 84550 | <1% | 1,951 | $6K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 124 | $6K |
| 73700 | <1% | 66 | $6K | |
| 84481 | <1% | 799 | $6K | |
| 84520 | <1% | 1,613 | $6K | |
| 77412 | <1% | 123 | $6K | |
| 84480 | <1% | 753 | $6K | |
| 90700 | <1% | 1,288 | $6K | |
| 83002 | <1% | 614 | $6K | |
| 72110 | <1% | 348 | $6K | |
| 58300 | <1% | 70 | $6K | |
| 86160 | <1% | 921 | $6K | |
| 82550 | <1% | 1,652 | $6K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 435 | $6K |
| 84270 | <1% | 443 | $6K | |
| 86200 | <1% | 692 | $5K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 20 | $5K |
| 95885 | <1% | 47 | $5K | |
| 62370 | <1% | 154 | $5K | |
| 64450 | <1% | 97 | $5K | |
| 83516 | <1% | 558 | $5K | |
| 86800 | <1% | 661 | $5K | |
| 73060 | <1% | 248 | $5K | |
| 84100 | <1% | 2,366 | $5K | |
| 85018 | <1% | 3,982 | $5K | |
| 98926 | <1% | 121 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,282 | $5K |
| 86256 | <1% | 566 | $4K | |
| 86592 | <1% | 349 | $4K | |
| 97035 | <1% | 52 | $4K | |
| 86334 | <1% | 591 | $4K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,633 | $4K |
| 80143 | <1% | 2,932 | $4K | |
| C1769 | Guide wire | <1% | 1,314 | $4K |
| 80051 | <1% | 312 | $4K | |
| 87077 | <1% | 510 | $4K | |
| 86364 | <1% | 354 | $4K | |
| 69210 | <1% | 344 | $4K | |
| 82977 | <1% | 720 | $4K | |
| 73552 | <1% | 254 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,762 | $4K |
| 74022 | <1% | 103 | $4K | |
| 82627 | <1% | 233 | $4K | |
| 83993 | <1% | 196 | $4K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,349 | $4K |
| 95908 | <1% | 570 | $4K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 669 | $4K |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 828 | $4K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,674 | $4K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 63 | $4K |
| C8924 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study | <1% | 23 | $4K |
| 88342 | <1% | 1,161 | $4K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 872 | $4K |
| 90674 | <1% | 424 | $4K | |
| 96523 | <1% | 63 | $3K | |
| 84144 | <1% | 153 | $3K | |
| 86308 | <1% | 378 | $3K | |
| 72052 | <1% | 151 | $3K | |
| 88142 | <1% | 255 | $3K | |
| 82784 | <1% | 625 | $3K | |
| 87800 | <1% | 200 | $3K | |
| 86235 | <1% | 623 | $3K | |
| 62369 | <1% | 41 | $3K | |
| 82803 | <1% | 2,986 | $3K | |
| 84132 | <1% | 983 | $3K | |
| 80320 | <1% | 167 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,442 | $3K |
| 84165 | <1% | 860 | $3K | |
| 86694 | <1% | 299 | $3K | |
| 84145 | <1% | 642 | $3K | |
| 73040 | <1% | 15 | $3K | |
| 20526 | <1% | 16 | $3K | |
| 90661 | <1% | 348 | $3K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 372 | $3K |
| 82951 | <1% | 160 | $3K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 16 | $3K |
| 87529 | <1% | 149 | $3K | |
| 83521 | <1% | 859 | $3K | |
| 85379 | <1% | 3,108 | $3K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 233 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,217 | $3K |
| 11900 | <1% | 42 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,970 | $3K |
| 88304 | <1% | 1,473 | $3K | |
| 83615 | <1% | 1,135 | $3K | |
| 87040 | <1% | 3,244 | $3K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 2,859 | $3K |
| 84155 | <1% | 982 | $3K | |
| 86258 | <1% | 224 | $3K | |
| 86665 | <1% | 336 | $3K | |
| 86618 | <1% | 265 | $2K | |
| 76870 | <1% | 208 | $2K | |
| 83498 | <1% | 180 | $2K | |
| 81015 | <1% | 960 | $2K | |
| 20605 | <1% | 19 | $2K | |
| 90656 | <1% | 376 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,758 | $2K |
| 90710 | <1% | 475 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 267 | $2K |
| 92551 | <1% | 27 | $2K | |
| 12011 | <1% | 15 | $2K | |
| 80179 | <1% | 2,894 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,972 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 25,918 | $2K |
| 76981 | <1% | 165 | $2K | |
| 20600 | <1% | 16 | $2K | |
| 80164 | <1% | 208 | $2K | |
| 10060 | <1% | 22 | $2K | |
| 43249 | <1% | 16 | $2K | |
| 76641 | <1% | 19 | $2K | |
| 99195 | <1% | 178 | $2K | |
| 93270 | <1% | 14 | $2K | |
| 80202 | <1% | 93 | $2K | |
| 88184 | <1% | 22 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 132 | $2K |
| 88185 | <1% | 44 | $2K | |
| 64415 | <1% | 32 | $2K | |
| 90461 | <1% | 6,120 | $2K | |
| 82150 | <1% | 1,863 | $2K | |
| 85014 | <1% | 806 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,806 | $2K |
| 82040 | <1% | 207 | $2K | |
| 97163 | <1% | 42 | $2K | |
| 82952 | <1% | 135 | $2K | |
| 00731 | <1% | 1,406 | $2K | |
| 86003 | <1% | 230 | $2K | |
| 95115 | <1% | 37 | $2K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 3,551 | $2K |
| 99382 | <1% | 27 | $1K | |
| 36416 | <1% | 4,920 | $1K | |
| 11720 | <1% | 83 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,885 | $1K |
| 93288 | <1% | 132 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,478 | $1K |
| 95024 | <1% | 140 | $1K | |
| 17003 | <1% | 608 | $1K | |
| 93298 | <1% | 92 | $1K | |
| 72146 | <1% | 16 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,111 | $1K |
| 80329 | <1% | 116 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,650 | $1K |
| 83721 | <1% | 168 | $1K | |
| 90688 | <1% | 133 | $1K | |
| 84478 | <1% | 312 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,301 | $1K |
| 85520 | <1% | 784 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,757 | $1K |
| 82140 | <1% | 700 | $996.00 | |
| 11301 | <1% | 12 | $994.18 | |
| 72220 | <1% | 41 | $975.12 | |
| 90381 | <1% | 118 | $971.95 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 20,185 | $970.23 |
| 00811 | <1% | 665 | $963.68 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,899 | $952.29 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 530 | $901.70 |
| 86704 | <1% | 80 | $883.70 | |
| 83921 | <1% | 277 | $858.50 | |
| 87106 | <1% | 524 | $855.95 | |
| 82103 | <1% | 118 | $846.08 | |
| 86580 | <1% | 43 | $845.00 | |
| 82010 | <1% | 708 | $842.09 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,876 | $806.08 |
| 82465 | <1% | 213 | $770.32 | |
| 93289 | <1% | 50 | $720.63 | |
| 86381 | <1% | 92 | $707.76 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,334 | $695.13 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,470 | $679.88 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 666 | $653.98 |
| 94010 | <1% | 13 | $638.06 | |
| 86147 | <1% | 19 | $625.46 | |
| 82378 | <1% | 226 | $609.93 | |
| 83010 | <1% | 100 | $582.71 | |
| 51798 | <1% | 286 | $576.20 | |
| 83520 | <1% | 31 | $559.26 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,016 | $556.99 |
| 86696 | <1% | 46 | $536.40 | |
| 90474 | <1% | 906 | $531.89 | |
| 90380 | <1% | 64 | $520.45 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 251 | $508.60 |
| 86039 | <1% | 70 | $506.36 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 60 | $487.48 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,864 | $480.41 |
| 76942 | <1% | 478 | $464.52 | |
| 90744 | <1% | 49 | $455.40 | |
| 73660 | <1% | 16 | $443.21 | |
| 82374 | <1% | 129 | $440.23 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 50 | $439.90 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,322 | $427.05 |
| 87581 | <1% | 29 | $412.52 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,458 | $408.54 |
| 72050 | <1% | 18 | $393.65 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 236 | $374.38 |
| 96417 | <1% | 697 | $369.59 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 734 | $346.17 |
| 82390 | <1% | 65 | $344.20 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 156 | $324.76 |
| 01400 | <1% | 38 | $317.64 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,488 | $298.07 |
| 82785 | <1% | 35 | $292.81 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 355 | $288.02 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 25 | $286.62 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 36 | $275.59 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,594 | $267.04 |
| 90649 | <1% | 26 | $265.30 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 538 | $261.80 |
| 84295 | <1% | 144 | $256.12 | |
| 84207 | <1% | 30 | $249.51 | |
| 90694 | <1% | 220 | $248.37 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 29 | $245.00 |
| 88300 | <1% | 179 | $241.19 | |
| 84075 | <1% | 140 | $236.72 | |
| 87075 | <1% | 257 | $231.71 | |
| 82787 | <1% | 60 | $229.08 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,619 | $226.94 |
| 82435 | <1% | 129 | $225.47 | |
| 86757 | <1% | 23 | $225.21 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,301 | $222.39 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,445 | $221.22 |
| 90698 | <1% | 41 | $218.76 | |
| 87486 | <1% | 29 | $213.28 | |
| 86920 | <1% | 22 | $210.46 | |
| 86705 | <1% | 12 | $209.88 | |
| 85045 | <1% | 106 | $207.80 | |
| 85613 | <1% | 48 | $199.17 | |
| 87476 | <1% | 20 | $190.87 | |
| 90714 | <1% | 14 | $190.78 | |
| 82310 | <1% | 40 | $189.60 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 364 | $175.00 |
| G0009 | Administration of pneumococcal vaccine | <1% | 295 | $174.74 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 523 | $164.60 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 1,476 | $157.94 |
| 82652 | <1% | 24 | $153.93 | |
| 84630 | <1% | 30 | $148.69 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,644 | $140.02 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 42 | $129.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 115 | $124.69 |
| 84134 | <1% | 29 | $124.25 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 120 | $123.56 |
| 90653 | <1% | 127 | $122.64 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 395 | $121.82 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 502 | $120.88 |
| C1729 | Catheter, drainage | <1% | 148 | $120.07 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,519 | $116.14 |
| 86812 | <1% | 15 | $104.36 | |
| 80177 | <1% | 15 | $101.31 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,770 | $99.60 |
| 72170 | <1% | 13 | $97.29 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,536 | $96.06 |
| 82525 | <1% | 13 | $91.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 488 | $91.69 |
| 82365 | <1% | 100 | $91.07 | |
| 84300 | <1% | 76 | $85.48 | |
| 87468 | <1% | 12 | $77.95 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 173 | $77.78 |
| 51702 | <1% | 37 | $75.02 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 881 | $74.07 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 16 | $70.63 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 25 | $68.17 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 252 | $67.62 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 131 | $66.64 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 602 | $65.92 |
| 87430 | <1% | 150 | $65.41 | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 30 | $64.05 |
| 83090 | <1% | 26 | $61.11 | |
| 88108 | <1% | 71 | $57.16 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 33 | $57.01 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 90 | $55.28 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 97 | $53.86 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 316 | $53.62 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,257 | $51.09 |
| 88173 | <1% | 25 | $48.14 | |
| 12032 | <1% | 13 | $40.60 | |
| 87469 | <1% | 12 | $38.97 | |
| 87484 | <1% | 12 | $38.97 | |
| 94375 | <1% | 49 | $38.84 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 450 | $37.67 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 9,866 | $33.75 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,600 | $33.20 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 786 | $32.79 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 200 | $31.56 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 216 | $28.52 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 44 | $28.17 |
| 82330 | <1% | 25 | $26.43 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 739 | $25.83 |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 465 | $24.19 |
| 90662 | <1% | 42 | $22.75 | |
| 99495 | <1% | 195 | $17.64 | |
| 83935 | <1% | 25 | $16.78 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 609 | $16.25 |
| 86695 | <1% | 13 | $16.08 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 245 | $15.69 |
| 85347 | <1% | 36 | $13.48 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 420 | $12.64 |
| 94760 | <1% | 1,982 | $10.57 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 403 | $8.83 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 38 | $5.98 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 567 | $4.39 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 267 | $4.02 |
| J3590 | Unclassified biologics | <1% | 12 | $1.76 |
| C1758 | Catheter, ureteral | <1% | 482 | $1.25 |
| 94761 | <1% | 2,927 | $0.07 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,873 | $0.00 |
| 01810 | 0% | 774 | $0.00 | |
| 99218 | 0% | 137 | $0.00 | |
| 92504 | 0% | 136 | $0.00 | |
| 01830 | 0% | 228 | $0.00 | |
| 23350 | 0% | 15 | $0.00 | |
| 88302 | 0% | 35 | $0.00 | |
| 00812 | 0% | 147 | $0.00 | |
| 00400 | 0% | 32 | $0.00 | |
| 95874 | 0% | 13 | $0.00 | |
| 87420 | 0% | 16 | $0.00 | |
| 72202 | 0% | 49 | $0.00 | |
| 00918 | 0% | 47 | $0.00 | |
| 92579 | 0% | 15 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 16 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 14 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 19 | $0.00 |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | 0% | 75 | $0.00 |
| A9270 | Non-covered item or service | 0% | 479 | $0.00 |
| 72020 | 0% | 670 | $0.00 | |
| 00813 | 0% | 1,038 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 582 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 925 | $0.00 |
| 87807 | 0% | 153 | $0.00 | |
| 99243 | 0% | 171 | $0.00 | |
| 77001 | 0% | 42 | $0.00 | |
| 00790 | 0% | 151 | $0.00 | |
| 00126 | 0% | 116 | $0.00 | |
| 90480 | 0% | 131 | $0.00 | |
| 95249 | 0% | 13 | $0.00 | |
| 96380 | 0% | 40 | $0.00 | |
| 01480 | 0% | 60 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 33 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 14 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 24 | $0.00 |
| 95910 | 0% | 17 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSENBERGER, ROBERT (CFO)
| Provider | Location | Paid |
|---|---|---|
| Valley Medical Facilities, INC. | Sewickley, PA | $19.37M |
| Valley Medical Facilities INC | Beaver, PA | $10.29M |
| Valley Medical Facilities INC | Sewickley, PA | $4.22M |
| Valley Medical Facilities, INC. | Sewickley, PA | $3.71M |
| Valley Medical Facilities, INC. | Mc Kees Rocks, PA | $1.86M |
| Valley Medical Facilities INC | Mc Kees Rocks, PA | $80K |
| Valley Medical Facilities, INC. | Wexford, PA | $32K |
| Valley Medical Facilities, INC. | Bellevue, PA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.